Epizyme, Inc., a clinical stage biopharmaceutical company creating
innovative personalized therapeutics for patients with genetically
defined cancers, today announced the publication on the website of the
American Society of Hematology (ASH) of an abstract entitled “The DOT1L
Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients
with MLL-Rearranged Leukemia”. The abstract contains preliminary data
from the Phase 1 trial of EPZ-5676, a potent and selective inhibitor of
the DOT1L histone methyltransferase (HMT). EPZ-5676 is being developed
for the treatment of acute leukemia with alterations in the MLL
gene (MLL-r) or partial tandem duplications within MLL (MLL-PTD).
The Company plans to present updated data from the trial at the 56 th
annual meeting of ASH in San Francisco, Calif.
Fiscal 2014 Results (compared to last year) - Total revenue decreased 12% to $2.1 billion - Social gaming revenue increased 28% to $281 million and average bookings per daily active user grew 16% to $0.43
- Adjusted earnings per share decreased 14% to $1.09 - GAAP earnings per share decreased 4% to $0.99 - Returned $319 million to shareholders in the form of share repurchases and dividends Fourth Quarter Results (compared to last year's fourth quarter) - Total revenue decreased 15% to $537 million - Social gaming revenue increased 22% to $75 million and average bookings per daily active user grew 15% to $0.46 - Adjusted earnings per share increased 23% to $0.37 - GAAP earnings per share increased 17% to $0.28 LAS VEGAS , Nov.
First Quarter Revenues of $280.1 Million, up 28.5% on a Reported Basis and up 28.1% on a Constant Currency Basis; Adjusted EBITDA up 20.7% on a Reported Basis and up 20.7% on a Constant Currency Basis; Company Updates Guidance, Announces Quarterly Dividend and Provides Supplemental Information
WESTLAKE, Texas , Nov.
Chesapeake Granite Wash Trust (NYSE:CHKR) (the “Trust”) today announced
that its common unit distribution for the quarter ended September 30,
2014 (which primarily relates to production attributable to the Trust’s
royalty interests from June 1, 2014 through August 31, 2014) will be
$0.5079 per common unit.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative
RNA-based therapeutics, today reported financial results for the three
and nine months ended September 30, 2014, and provided an update of
recent corporate developments.
Plains All American Pipeline, L.P. (NYSE: PAA )
today announced that it has entered into a definitive purchase and sale
agreement with Occidental Petroleum Corporation for the purchase by PAA
of Occidental’s 50% interest in BridgeTex Pipeline Company LLC
(“BridgeTex”) for $1.075 billion.
-GAIN reports record net revenue of $103.7 million amid improved trading conditions -Commission revenue of $35.0 million; represented 34% of total net revenue
-Net income more than doubled to $15.3 million or $0.33 per diluted share -Adjusted EBITDA more than doubled to $27.5 million BEDMINSTER, N.J. , Nov.
MasterCard (NYSE:MA) today announced it has entered into an agreement to
acquire the Payment Gateway Services business of Transaction Network
Services (TNS). The business will join DataCash in expanding
MasterCard’s global payment gateway solutions.
SurModics, Inc. (NASDAQ: SRDX), a leading provider of surface
modification and in vitro diagnostic technologies to the healthcare
industries, today announced results for its fiscal 2014 fourth quarter.
- SECOND QUARTER AND SIX MONTH GAAP NET INCOME OF $26.1 MILLION ($0.73 PER DILUTED SHARE) AND $70.2 MILLION ($1.96 PER DILUTED SHARE) - SECOND QUARTER AND SIX MONTH ADJUSTED NET INCOME OF $31.1 MILLION ($0.87 PER DILUTED SHARE) AND $78.4 MILLION ($2.19 PER DILUTED SHARE)
- SECOND QUARTER RESULTS IMPACTED BY NON-CASH FOREIGN CURRENCY VOLATILITY, WHILE BRISTOW VALUE ADDED AND LIQUIDITY IMPROVED - COMPANY REAFFIRMS GUIDANCE FOR FULL FISCAL YEAR 2015 ADJUSTED EPS OF $4.70 - $5.20 HOUSTON , Nov.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.